



IAP3 Rec'd PCT/PTO 13 JAN 2006

PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
Adrian MERLO et al. : **Mail Stop: PCT**  
Serial No. 10/549,665 : Attorney Docket No. 2005\_1392A  
Filed September 19, 2005 :

RADIOPHARMACEUTICALS FOR CANCER  
DIAGNOSIS AND TREATMENT  
[Corresponding to PCT/EP2004/050329  
Filed March 18, 2004]

### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☐ each U.S. Patent and U.S. Patent application publication;
- ☒ each reference previously cited in the international application  
PCT/EP2004/050329; and/or
- ☐ each reference previously cited in prior parent application Serial No.  
\_\_\_\_\_

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

**and thus no certification and/or fee is required.**

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and**

**the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified


a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or

b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
  - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
  - c. ☐ the concise explanation contained in the specification of the present application at page,
  - d. ☐ the concise explanation set forth in the attached English language abstract,
  - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☐ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Adrian MERLO et al.

By   
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
January 13, 2006

## INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: January 13, 2006

ATTY DOCKET NO.  
2005\_1392ASERIAL NO.  
10/549,665APPLICANT  
Adrian MERLO et al.FILING DATE  
September 19, 2005

GROUP



## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AG	02/24235	3/2002	WO			
	AH	01/02021	1/2001	WO			
	AI	1 283 216	2/2003	EP			
	AJ						
	AK						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AL	A. Heppeler et al., "Receptor Targeting for Tumor Localisation and Therapy with Radiopeptides", Current Medicinal Chemistry, Vol. 7, No. 9, pp. 971-994, 2000.
	AM	T. K. Nikula et al., "Improved Method for Labelling DOTA-Analogues with <sup>213</sup> Bi, <sup>225</sup> Ac and Lanthanides", Abstracts of Papers 225 ACS National Meeting, March 23, 2003, page Nucl-67 (1), XP008023978, Abstract.
	AN	J. Fichna et al., "Synthesis of Target-Specific Radiolabeled Peptides for Diagnostic Imaging", Bioconjugate Chem., Vol. 14, pp. 3-17, 2003.
	AO	M. Laznicek et al., "Octreotide and Octreotate Derivatives Radiolabeled with Yttrium: Pharmacokinetics in Rats", Cancer Biotherapy & Radiopharmaceuticals, Vol. 17, No. 5, pp. 527-533, 2002.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.